Objective: To examine whether antenatal steroids (ANS), alone or with early indomethacin, are associated with spontaneous intestinal perforation (SIP). SIP is a known complication of concurrent post-natal administration of glucocorticoid and indomethacin in extremely low birth weight (ELBW) infants.
Introduction
The use of antenatal steroids (ANS) in women with premature labor has been reported since 1972, and has become the standard of care within the United States since the early 1990s. 1 Their overall positive effect on neonatal mortality and morbidity has been repeatedly documented in a variety of gestational age infants including the extremely low birth weight (ELBW) population. [2] [3] [4] Spontaneous intestinal perforation (SIP) is a disease of the developing intestinal tract that appears to involve two populations of infants: the ELBW infant and an older, heavier population of infants. 5 In ELBW infants, the histopathology has been associated with hypertrophy of the intestinal mucosa and a concomitant thinning of the submucosa. 6 This histopathology has been reproduced in a newborn mouse model using post-natally administered glucocorticoid to induce mucosal hypertrophy. 7 Clinically the post-natal glucocorticoid effect can been magnified by the concomitant use of indomethacin, a fact that has terminated two large multicenter trials investigating prophylactic glucocorticoids. 8, 9 In these trials, it was suggested that coadministration of indomethacin with post-natal glucocorticoids was a causal relationship of SIP. It has been postulated that ANS might affect the incidence of SIP both favorably (by suppression of endogenous adrenal output), and adversely (by direct effect on intestinal tissues when given near the time of birth concurrently with early post-natal indomethacin). [10] [11] [12] The effect of ANS when given in combination with early indomethacin has not been examined to date and forms the basis of the current investigation.
Materials and methods
Clinical data on neonates managed at a Pediatrix site were recorded during the time that care was provided in the neonatal intensive care unit (as described previously). 5 The use of the data and certification of the data as deidentified was approved by the University of Virginia Human Investigation Committee (Charlottesville, VA, USA) and the Wichita Medical Research and Education Foundation (Wichita, KS, USA). In brief, infants with a diagnosis of acquired bowel disease were identified and categorized as SIP or necrotizing entrocolitis. Subsequent analysis of the SIP group revealed two populations of infants: an early (0 to 3) days of life and late group (4 to 14 days of life). 5 In our previous paper (J Perinatol; 26 (3): 185-188) we delineated two forms of SIP that differ in their timing of presentation and occur in two distinct gestational populations of preterm neonates. The early (0 to 3 days) perforation group was a heterogenous population in terms of birth weight and gestational age and therefore was unlikley to represent a meaningful cohort. Because they were more mature and larger, the early (0 to 3 days) group were less often exposed to ANS and less often had a report of a patent ductus arteriosus (PDA) (J Perinatol; 26 (3): 185-188). Neither examing them as a distinct cohort nor combining them to enhance the size of our cohort would improve the likelihood of significance difference in favor of either hypothesis. The cohort examined is the most appropriate for the literature. A matching algorithm was used to identify infants based on gender and birth weight (±20 g). Each infant with SIP was matched to a control group infant (1:1). The two groups (perforation between 4 and 14 days of life and the control group) were then compared. To examine the medications of interest for bowel perforation, the 'Medications' table was queried for any report of 'hydrocortisone', 'dexamethasone' or 'indomethacin' within each of the first 14 days of life in both control and perforation cohorts to look at each day of exposure. Early (defined as 0 to 3 days of life) drug exposure to the medications of interest was noted. The reporting of ANS was done at the time of diagnosis and recorded as a categorical variable (timing and number of doses was not recorded).
Study populations were compared using both univariate and bivariate techniques. Continuous variables (estimated gestational age and birth weight) were evaluated with two-tailed t-tests. Categorical variables (e.g., race and gender) were evaluated with a two-tailed w 2 test. Nonparametric continuous data were assessed with a Kruskal-Wallis analysis of variance.
After univariate analysis, multivariate logistic regression was used to identify factors independently associated with SIP compared to matched controls. The demographic variables found by univariate analysis to be significantly different for the two groups (P<0.1) were used in the logistic regression analysis. Variables were entered into the model with a stepwise selection (P-value for entry and retention <0.1). Multivariate analysis was also used to assess for independence between drugs that were found to be associated with a diagnosis of SIP when given within the adjacent treatment windows.
Results
During the epoch covered by this data set, there were 2 27 711 infants cared for at Pediatrx sites. Previous work by the authors had shown that there were two populations of infants that carried the diagnosis of intestinal perforation: a group of infants that developed perforations early (days 0 to 3) and a group that developed perforation late (days 4 to 14). In this the third review of the data set, the authors limited the analysis to 388 infants in whom the diagnosis of SIP was made between days 4 and 14 of life.
There was no difference in the estimated gestational age, birth weight, APGAR scores, or ANS exposure between the SIP infants and the control group (Table 1) . As we had previously noted, infants with SIP were more likely to have been outborn and have received early post-natal indomethacin and glucocorticoids. When the groups were examined for the combination of ANS with indomethacin, we did find significant differences in exposure between groups (Table 2a) . Infants in the control group were more likely to have been exposed to ANS without subsequent addition of indomethacin, but this association was not significant (P ¼ 0.2). The SIP group had significantly higher rates of infants exposed to indomethacin alone as well as ANS plus indomethacin (P<0.05 for each). The combination of the ANS with indomethacin was not associated with an increased number of infants developing SIP when compared to indomethacin use alone. (Table 2b ) (odds ratio 1.02; confidence interval 0.62 to 1.69).
Multivariate analysis was used to examine factors independently associated with SIP. They included were being outborn, a report of a PDA as a diagnosis, a report of the use of indomethacin and the use of hydrocortisone within the first 3 days of life (Table 3) . ANS were not found to be associated with SIP.
Discussion
Our understanding of the pathogenesis of SIP in ELBW newborns has evolved sporadically. Much of this knowledge has been owing to secondary outcomes when examining the effects of post-natal glucocorticoids on the ELBW population in randomized trials. Unfortunately the reliability of secondary outcomes, particularly when not defined before the onset of a trial, can be hard to judge. Despite these limitations, the associations with post-natal glucocorticoids and concommitant early indomethacin have become fairly well accepted, in large part owing to the Stark and Watterberg trials. However, we are aware of only one report to date analyzing ANS with regard to this disease. 11 The data set used in this manuscript has the largest collection of infants with SIP reported to date and lends itself to analyses of pharmacologic variables that are associated with SIP. Although positive associations in retrospective cohort analyses should never be construed as causal relationships, we feel confident that a negative association in a cohort of this size is strong evidence for non-causality. To that end, Dr Gordon's previous hypothesis that ANS and indomethacin are synergistic risk factors for SIP should be rejected. 5, 10, 12 Likewise, we were unable to find support for Dr Watterberg's hypothesis that ANS reduces the incidence of SIP.
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What we found instead was that early indomethacin was Antenatal steroids are not associated with SIP JT Attridge et al persistently associated with SIP, regardless of ANS exposure. It is possible that either Dr Gordon's or Dr Watterberg's postulates might still be validated if the precise timing of ANS dosing before birth were taken into account (in this data set, ANS was reported as a categorical variable and timing of dose was not included); but the size of our data set suggests that the magnitude of such an effect (in whichever direction) would be small. This is perhaps worth further thought, as there may something uniquely vulnerable about the immediate post-natal window compared to the antenatal and perhaps the more distant post-natal periods with regard to drug exposure. 13 During this window the distal intestine undergoes rapid remodeling and we now know that it is extremely steroid sensitive. [14] [15] [16] The mucosa has been reported to have more cortisteroid receptor in late gestation that at any other time of life, yet in utero the distal intestine expresses 11-betahydroxysteroid dehydrogenase and retards its maturation. [17] [18] [19] It is clear that these finely tuned counter regulatory functions are not meant to be perturbed in the late second trimester, which is what happens when an ELBW infant is born. What is unclear is how indomethacin interacts with the intestine at this stage of prematurity. In this investigation we were unable to show any association (protective or harmful) between ANS (combined with indomethacin or when used alone) and SIP. Antenatal steroids are not associated with SIP
